New Study Identifies Better Treatment Option for Common Complication of Dialysis
Use of drug-coated balloon angioplasty to treat blocked blood vessels used for hemodialysis offers hope for millions of patients globally
A Mount Sinai-led study has identified a better treatment option for a common complication of hemodialysis, bringing new hope to millions of patients who rely on dialysis to survive but often must undergo repeated hospital visits to make continued treatment possible.
The study, published today in The New England Journal of Medicine, used drug-coated balloon angioplasty to treat arteriovenous fistulas, access points created by surgeons through which the patient’s blood can be removed, sent through the dialysis machine to have impurities filtered out, and returned to the patient’s body. Hemodialysis fistulas frequently become blocked and stop working. This has traditionally been treated by either inserting a stent to keep the fistula open, or by standard angioplasty, in which a tiny balloon is threaded through the blood vessel and then expanded to force the fistula open. Both procedures are commonly used, but in many cases, they only are able to keep the vessel open for a few months.
“Patients with this debilitating disease frequently require multiple visits to the hospital for treatment and face a life-long battle to maintain their access point used for dialysis,” said Robert A. Lookstein, MD, MHCDL, Professor of Radiology, and Surgery, at the Icahn School of Medicine at Mount Sinai and Executive Vice Chair of Diagnostic, Molecular, and Interventional Radiology at Mount Sinai Health System, who led the international team of investigators. “The access points often become blocked or damaged and unable to be used, requiring multiple procedures or interventions to restore the function of the access.”
Nearly 2.5 million patients worldwide regularly undergo hemodialysis, according to the European Renal Care Provider Association.
In this prospective, randomized trial (IN.PACT AV, Medtronic access study), 170 subjects were assigned to receive treatment with a drug-coated balloon and 160 were assigned to receive treatment with a standard balloon. Patients who received the drug-coated balloon were 25 percent more likely to still have a functioning access point after 6 months, compared to those receiving the standard balloon treatment. In addition, the number of procedures required to maintain the opening was decreased by over 50 percent for those who received the drug coated balloon.
“This treatment has the potential to offer patients with end-stage renal disease continuous hemodialysis, avoiding unnecessary procedures and surgeries which can dramatically affect patients over the course of their lives. This is a game changer for patients who are often tethered to a health care facility for treatment and maintenance of a poorly functioning dialysis access. If we can reduce the number of interventions and keep these patients out of the hospital, we can dramatically improve their quality of life,” said Dr. Lookstein.
This research was supported by Medtronic.
About the Mount Sinai Health System
Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with 48,000 employees working across eight hospitals, more than 400 outpatient practices, more than 600 research and clinical labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time—discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.
Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 9,000 primary and specialty care physicians and 11 free-standing joint-venture centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida. Hospitals within the System are consistently ranked by Newsweek’s® “The World’s Best Smart Hospitals, Best in State Hospitals, World Best Hospitals and Best Specialty Hospitals” and by U.S. News & World Report's® “Best Hospitals” and “Best Children’s Hospitals.” The Mount Sinai Hospital is on the U.S. News & World Report® “Best Hospitals” Honor Roll for 2024-2025.
For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.